Fault for High Priced Drugs Lies with Drug Makers   

John D. Jones, RPh, JD, FAMCP
An expert on managed care pharmacy practice, pharmacy law, regulation and policy.

When it comes to how high they price their products, drug companies want the public to ignore what they spend on marketing and the tax breaks they get for direct-to-consumer advertising. Instead of simply acknowledging their pricing strategies, drug companies and their lobbyists have launched a finger-pointing campaign at pharmacy benefit managers (PBMs). This isn’t […]

Read more